Hunan Children's Hospital
Hunan Children's Hospital
Changsha, Hunan, China10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature | Idiopathic Short Stature (ISS) | Not yet recruiting | Phase 3 | 2026-09-11 | NCT07815626 | |
| Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-07-23 | NCT06764238 | |
| A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children | Infections, Mononegavirales infectious disease, Paramyxoviridae infectious disease, Pneumovirus Infections, RNA Virus Infections, respiratory syncytial virus infectious disease, viral infectious disease | Recruiting | Phase 3 | 2026-04-02 | NCT07402512 | |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature | Idiopathic Short Stature | Recruiting | Phase 3 | 2026-03-11 | NCT06927310 | |
| Newly-diagnosed Pediatric Ph-positive B-ALL Protocol | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2025-09-03 | NCT07152041 | |
| Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2025-08-26 | NCT06882057 | |
| Newly-diagnosed Pediatric T-cell ALL Protocol | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 / Phase 3 | 2025-08-26 | NCT06855810 | |
| A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature | Bone Diseases, Developmental, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dwarfism, bone disorder, endocrine system disorder, hereditary disease, musculoskeletal system disorder | Active, not recruiting | Phase 2 | 2025-08-15 | NCT03255694 | |
| Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature | Short Stature Children Born Small for Gestational Age (SGA) | Active, not recruiting | Phase 2 | 2025-05-25 | NCT02375620 | |
| A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Not yet recruiting | Phase 3 | 2025-01-10 | NCT06767540 |